Healthtech startup 4baseCare has raised INR 90 Cr ($9.8 Mn) as part of its ongoing Series B funding round, co-led by prominent investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backer Yali Capital. The Bengaluru-based precision oncology platform will use the fresh capital to expand its hospital-linked genomics laboratory network across India and strengthen its presence in international markets including the Middle East, Southeast Asia, Latin America, and Central Asia. This funding follows a prior INR 50 Cr ($5.4 Mn) Series A round and builds momentum for the company’s AI-driven clinical decision support solutions.

Funding Details and Capital Allocation

This latest tranche represents the first close of 4baseCare‘s Series B round, bringing significant investor firepower to support ambitious scaling plans. The round attracted high-profile backing from Ashish Kacholia—often called the “Big Whale” of Indian investing—alongside Lashit Sanghvi, signaling strong conviction in the company’s trajectory. Yali Capital‘s continued participation underscores sustained belief from early supporters, while prior investments from Infosys Innovation Fund (INR 8.3 Cr minority stake) and a Karnataka government grant further validate the platform’s potential.

The capital will fuel two primary objectives. First, expanding the hospital-linked genomics laboratory footprint to enhance accessibility of precision cancer diagnostics. Second, accelerating development of AI-powered clinical decision support tools, particularly OncoTwin Insights. This platform provides oncologists with actionable treatment recommendations derived from real-world clinico-genomic datasets and patient outcomes, recently selected for Memorial Sloan Kettering Cancer Centre‘s MSK iHub programme. CEO Hitesh Goswami emphasized: “This funding will help us scale globally while building OncoTwin as an AI-driven decision support platform that learns from real-world clinico-genomic outcomes.“

Core Technology and Precision Oncology Platform

Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare addresses critical gaps in cancer care through comprehensive genomic profiling and AI analytics. The company’s flagship TARGT Indiegene test combines next-generation sequencing (NGS) with clinical data integration to deliver personalized therapy recommendations, matching patients to targeted treatments, immunotherapies, and clinical trials. Operating laboratories in India, the Philippines, Nepal, and Dubai, 4baseCare has served over 10,000 patients, establishing clinical credibility among oncologists.

The platform’s differentiation lies in its population-relevant databases that merge large-scale genomic data with clinical, environmental, and lifestyle information. OncoTwin Insights represents the next evolution, enabling real-world evidence (RWE)-based treatment benchmarking across diverse populations where clinical trial data remains sparse. This approach proves particularly valuable in emerging markets facing rising cancer incidence but limited access to precision medicine infrastructure.

Strategic Expansion Roadmap

Domestic priorities target Tier-1 and Tier-2 cities where cancer burden escalates alongside healthcare digitization. International expansion focuses on regions sharing epidemiological profiles and regulatory compatibility: Middle East (hospital partnerships), Southeast Asia (population-scale genomics), Latin America (oncology network integration), and Central Asia (early diagnostics adoption). The hospital-linked laboratory model minimizes turnaround times while embedding genomic testing within clinical workflows.

AI investments extend beyond OncoTwin to multi-modal analytics incorporating radiology, electronic health records, and longitudinal outcomes. Regulatory milestones include certifications for target markets and reimbursement pathway development, essential for sustainable scaling. Partnerships with hospital chains, diagnostic networks, and pharmaceutical companies accelerate protocol adoption and evidence generation.

Market Context and Competitive Landscape

India confronts a cancer epidemic—1.5 million new cases annually—against fragmented diagnostics and suboptimal outcomes due to empirical treatment approaches. While sequencing providers like MedGenome dominate raw genomics, 4baseCare’s end-to-end platform spans testing, AI insights, and RWE analytics. Global parallels like Tempus and Guardant Health validate the model, but 4baseCare’s emerging-market pricing creates sustainable differentiation.

Healthtech funding rebounded in 2025 with $700 Mn deployed, concentrated in AI-diagnostic platforms per Inc42’s Annual Indian Startup Trends Report. Precision oncology attracts disproportionate capital amid falling NGS costs and pharmaceutical companion diagnostic demand. The sector’s projected 39% CAGR trajectory toward $37 Bn by 2030 underscores timing alignment.

Leadership and Strategic Validation

Hitesh Goswami combines scientific rigor with commercialization expertise, supported by an advisory board of globally recognized oncologists. Infosys’s strategic minority stake through its Innovation Fund signals enterprise validation, potentially unlocking co-development opportunities. Ashish Kacholia and Lashit Sanghvi highlighted: “4baseCare is building a powerful genomics and AI-driven clinical intelligence platform for inclusive precision oncology. With strong hospital partnerships… the company is well positioned to scale across emerging markets.“

Karnataka government grants reflect state-level recognition of 4baseCare’s innovation ecosystem contributions. The company’s trajectory—from 2018 founding to multi-hundred crore valuation—mirrors category-defining healthtech peers while maintaining clinical focus.

Challenges and Growth Catalysts

Scaling demands navigating regulatory complexity across jurisdictions, clinician adoption barriers, reimbursement negotiations, and data privacy compliance (DPDP Act, GDPR equivalents). Genomic sequencing costs require continued optimization for mass-market viability. International expansion introduces currency fluctuations and localized evidence requirements.

Tailwinds prove compelling: Declining NGS economics, AI democratization, government cancer grids, and biopharma’s real-world evidence hunger. Near-term milestones target 50,000 cumulative patients, three international laboratories, and published clinical utility studies by Q4 2026.

Industry Transformation Potential

Success positions 4baseCare to catalyze India’s precision medicine ecosystem, upskilling oncologists in data-driven practice and establishing Bengaluru as a clinico-genomic research hub. Pharmaceutical collaborations for basket trials and RWE generation diversify revenue beyond diagnostics. International scaling could mirror Narayana Health’s model—high-quality care at emerging-market prices.

For investors, 4baseCare exemplifies deep-tech healthtech: Domain-specific AI achieving clinical-commercial scale. Payer-provider partnerships, insurance reimbursement pathways, and government tender wins represent additional growth vectors.

Conclusion: Precision Oncology’s Emerging Market Champion

4baseCare’s $9.8 million Series B close marks a pivotal inflection point, transforming precision oncology from elite privilege to population reality. By fusing genomic sequencing, AI decision support, and real-world evidence, the company addresses systemic gaps affecting millions across price-sensitive geographies.

As global oncology shifts from empirical to genomic paradigms, 4baseCare emerges strategically positioned—anchored by marquee investors, validated by clinical partnerships, and powered by scalable technology. From Bengaluru laboratories to Middle East hospital networks, the company’s execution will shape precision medicine’s next decade. Healthcare stakeholders, biopharma innovators, and emerging-market investors should track this trajectory closely—accessible cancer intelligence arrives not a moment too soon.